Understand the source comparison
Peptides and Magnesium Synergy Timing Protocol: Form and Timing Comparison
| Magnesium Form | Absorption Rate | Timing Before Injection | Tissue Saturation Window | Proteolytic Protection Level | Recommended Dose | Professional Assessment ||—|—|—|—|—|—|| Magnesium Glycinate | Moderate (45–55% bioavailable) | 45–60 minutes | Peaks at
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- | Magnesium Form | Absorption Rate | Timing Before Injection | Tissue Saturation Window | Proteolytic Protection Level | Recommended Dose | Professional Assessment ||—|—|—|—|—|—|| Magnesium Glycinate | Moderate (45–55% bioavailable) | 45–60 minutes | Peaks at 90 minutes post-dose | Moderate (reduces degradation 18–24%) | 300–400mg elemental | Best all-purpose option. Reliable tissue uptake without GI distress || Magnesium Threonate | High (70–80% CNS uptake) | 30–45 minutes | Peaks at 60 minutes post-dose | High for CNS peptides (reduces degradation 28–35%) | 144mg elemental (2g Magtein) | First choice for nootropic peptides targeting GPCR pathways in neural tissue || Magnesium Oxide | Very Low (4–10% bioavailable) | Not applicable | Does not achieve tissue saturation | Negligible | Not recommended | Useless for this protocol. Too little reaches interstitial fluid || Magnesium Citrate | Moderate-High (60–70% bioavailable) | 30–60 minutes | Peaks at 75 minutes post-dose | Moderate-High
- This table isolates the critical variables: bioavailability determines how much magnesium reaches interstitial fluid, timing determines whether it's present when the peptide arrives, and proteolytic protection level reflects measurable reduction in peptide degradation during the first hour post-injection. Magnesium threonate dominates for CNS-targeted peptides because it crosses the blood-brain barrier efficiently. Critical for compounds like P21. Glycinate is the workhorse for systemic peptides. Reliable, well-tolerated, and reaches therapeutic tissue levels within the required window.